Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying (NASDAQ:SMMT)

I'm rating Summit Therapeutics ( SMMT ) as a "cautious buy" due to the promising combination of anti-PD-1 plus anti-VEGF. If the company manages to reach just 4% of market share in 2033, it implies a potential 15% annualized CAGR upside. ThisAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in SMMT over the next 72 ...